健之佳(605266.SH):擬通過門店向羣眾免費發放價值1000萬元的布洛芬片(或對乙酰氨基酚)
格隆匯12月30日丨健之佳(605266.SH)公佈,公司系疫情防控物資重點保供單位和儲備計劃任務企業,面對疫情高峯期退熱等藥品供應緊張的現狀,公司採購、物流及營運團隊日夜奮戰,爭取及時配送,全力保障市民抗疫物資及藥品供應,履行社會責任。
為解決羣眾困難,保障供應,公司緊急組織了價值1000萬元的布洛芬片(或對乙酰氨基酚),擬在監管部門的指導下,通過門店向羣眾免費發放,以積極履行“來源於社會、回報社會”的企業責任,幫助羣眾共度難關。同時,公司董事會授權管理層在整體不超出上述金額20%的範圍內,結合疫情防控及相關地區切實需求,辦理疫情防控相關捐贈事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.